Pearl Therapeutics

Pearl Therapeutics Focuses on the Development of Inhaled Small Molecule Therapies for the Treatment of Respiratory Diseases. PT003, Pearl’s Leading Product, is a Fixed-Dose Combination Product Comprising the Long-Acting Beta-2 Agonist (LABA) Formoterol Fumarate and the Long-Acting Muscarinic Antagonist (LAMA) Glycopyrrolate. The LABA/LAMA Combination is Expected to Become an Important New Class of COPD Medications.